Suite 1001, 4 Bridge St

Sydney NSW 2000

P: +61 2 9247 0070

E: pscomans@bigpond.com
W: www.bioxyne.com

Australian Securities Exchange Companies Announcements Office SYDNEY
18th February 2013 Status review of HI-164OV: Further update

Bioxyne Limited (ASX: BXN, the Company) announces headline results from a more complete analysis of Study HI-H005. The analysis was undertaken by Datapharm Australia, the Company's Contract Research Organisation (CRO) for the study, and was a post-hoc analysis of study data.

Key results in the data that excluded males 65 years of age and older were:

• Reduction in the number of patients having events of COPD by 30% (p=0.01)

• Reduction in the number of events of COPD by 31% (p=0.04)

• Beneficial effects in women of any age (30%, p=0.02) and people under 65 years (44%, p=-

.01).
The benefit to patients under 65 years confirming results released to the market in June 2012.
The study showed no benefit to males aged 65 and older with moderate or severe COPD. Men of this age group represent some 26% of patients with COPD.
An event of COPD is defined as occurring when a patient with COPD makes an unscheduled visit to the doctor and is prescribed corticosteroid treatment or they were admitted to hospital for worsening COPD.
The Company noted in its 28 June 2012 release to the market that the primary end-points of Study HI-H005, as it was planned, were not met, but that there was significant benefit in patients aged 65 years and below. This assessment update expands on the previous information.
For further information, contact
Dr Phillip Comans
Chief Executive Officer
Mobile: +61 (0)439 466 116
1

distributed by